[1] FDA. Label approved on 11/15/2010 for HALAVEN, NDA no. 201532[EB/OL]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf. [2] Twelves C, Cortes J, Vahdat L T, et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer[J]. Clin Breast Cancer, 2010,10(2):160-163. [3] JENNIFER A S, LESLIE W, OLGA AZARENKO, et al. Eribulin Binds at Microtubule Ends to a Single Site on Tubulin to Suppress Dynamic Instability[J]. Biochem， 2010, 49(6): 1331–1337. [4] JAVIER C, ALBERTO J M, STEFAN G. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer[J]. Cancer Treat Rev, 2011, 22（10）：1-12.
PDF(352 KB)
